Cerenome is trading at $1.67, down 10.70%, with no same-day company-specific negative catalyst identified.

  • The September 30 update reported 222 CNSide tests and $1.55 million in unaudited Q3 gross billings; it does not explain the October 1 decline.
  • Healthcare weakness amid rising Treasury yields may have added pressure, though major U.S. indexes were slightly higher. An October 1 report said Lake Street cut its price target but maintained a Buy rating; causation is unestablished.